Paul Johnson

Casey Alexander

Douglas Harter

Matthew Hurwit

Sean-Paul Adams

Bryce Rowe

Finian O'Shea

John Hecht

- Trinity Capital Inc. has committed **$130 million** in growth capital to Candel Therapeutics, Inc..  **[1786108_20251014LA96890:0]** 
- This financing will support Candel's clinical development of **CAN-2409** and pre-commercial and launch readiness activities for CAN-2409 in prostate cancer, pending regulatory approval.  **[1786108_20251014LA96890:0]** 
- Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, with leading therapies CAN-2409 and CAN-3110 targeting various solid tumors.  **[1786108_20251014LA96890:0]** 
- CAN-2409 has received multiple FDA designations, including Regenerative Medicine Advanced Therapy Designation (RMAT) for localized prostate cancer, Fast Track Designation for localized prostate cancer and non-small cell lung cancer, and Orphan Drug Designation for pancreatic ductal adenocarcinoma (PDAC).  **[1786108_20251014LA96890:0]** **[1786108_20251014LA96890:1]**

Trinity Capital Provides $130 Million Growth Capital to Candel Therapeutics

- Trinity Capital Inc. originated **$773 million of new commitments** in the **third quarter of 2025**, bringing total new commitments for the first three quarters of 2025 to **$1.5 billion**.  **[1786108_0001193125-25-235171_trin-ex99_1.htm:0]** 
- The company funded approximately **$471 million of investments** in the third quarter of 2025.  **[1786108_0001193125-25-235171_trin-ex99_1.htm:0]** 
- Proceeds received from repayments and exits of investments totaled approximately **$255 million** during the third quarter of 2025.  **[1786108_0001193125-25-235171_trin-ex99_1.htm:0]** 
- Trinity Capital Inc. plans to release its complete **third quarter 2025 financial statements on November 5, 2025**.  **[1786108_0001193125-25-235171_trin-20251009.htm:0]** **[1786108_0001193125-25-235171_trin-ex99_1.htm:0]**

Trinity Capital Inc. Announces Q3 2025 Portfolio Activity

- Trinity Capital originated **$773 million of new commitments** in the third quarter of 2025, bringing the total for the first three quarters of 2025 to **$1.5 billion**.  **[1786108_20251009LA94041:0]** 
- The company funded approximately **$471 million of investments** in Q3 2025, which included **$381 million in secured loans**, **$57 million in equipment financings**, and **$33 million in warrant and equity investments**.  **[1786108_20251009LA94041:0]** 
- For the first three quarters of 2025, total investments funded were approximately **$1.1 billion**, and proceeds received from repayments and exits totaled approximately **$607 million**.  **[1786108_20251009LA94041:0]** 
- Trinity Capital will release its complete third quarter 2025 financial results on **Wednesday, November 5, 2025**.  **[1786108_20251009LA94041:0]**

Trinity Capital announces Q3 2025 portfolio update

- **Trinity Capital Advisors** and Town Lane have acquired **440 South Church**, a **15-story, 388,657 square-foot Class-A office building** in Uptown Charlotte.  **[1786108_ea712e48ccfb4a4db23af54c854da803_0]** 
- The building is currently **mid-40s% occupied**, and the new ownership plans to invest **more than $20 million** in capital improvements and renovations immediately.  **[1786108_ea712e48ccfb4a4db23af54c854da803_0]** 
- Trinity Capital, which originally developed the building in **2009**, sees this acquisition as a strategic opportunity due to the property's basis being **over 70% below new construction costs** and the diminishing supply of Class-A office space in the Charlotte market.  **[1786108_ea712e48ccfb4a4db23af54c854da803_0]**

Trinity Capital and Town Lane Acquire 440 South Church

- **Trinity Capital Inc.** committed **$45 million** in growth capital to **Rapid Micro Biosystems**.  **[1786108_20250922LA78239:0]** 
- **Rapid Micro Biosystems** is an innovative life sciences technology company that provides automation solutions for microbial quality control, notably through its **Growth Direct® platform**.  **[1786108_20250922LA78239:0]** **[1786108_20250922LA78239:1]** 
- The new capital will be used to scale **Rapid Micro Biosystems'** operations, support the global commercial expansion of its platform, and fund investments aimed at driving gross margin expansion through product cost reduction and increased manufacturing efficiencies.  **[1786108_20250922LA78239:0]** 
- This partnership is expected to significantly strengthen **Rapid Micro Biosystems'** financial position and support its continued focus on long-term revenue growth, margin expansion, and increasing shareholder value.  **[1786108_20250922LA78239:0]**

Trinity Capital Provides Growth Capital to Rapid Micro Biosystems

- Trinity Capital Inc. (Nasdaq: TRIN) announced a commitment of **$100 million in growth capital** to Angel Studios, Inc. (NYSE: ANGX).  **[1786108_20250918LA76219:0]** 
- Angel Studios, a media and technology company, recently completed its business combination and its Class A common stock now trades on the New York Stock Exchange under the ticker symbol **"ANGX"**.  **[1786108_20250918LA76219:0]** 
- This investment supports Angel Studios' mission to bring uplifting content and expand the reach of its audience-empowered model.  **[1786108_20250918LA76219:0]**

Trinity Capital commits $100 million in growth capital to Angel Studios

- Trinity Capital Inc. announced a commitment of up to **$50 million** in growth funding to Nalu Medical, Inc., a commercial-stage medical device company.  **[1786108_20250916LA74313:0]** 
- Nalu Medical specializes in neurostimulation solutions for patients with chronic intractable neuropathic pain, utilizing its proprietary, minimally invasive, battery-free, and FDA-cleared implantable pulse generator (IPG) device.  **[1786108_20250916LA74313:0]** 
- The funding will support Nalu Medical's continued commercial expansion, including its newly launched next-generation Therapy Disc.  **[1786108_20250916LA74313:0]**

Trinity Capital Commits Up to $50 Million in Growth Funding to Nalu Medical

- Trinity Capital Inc. (TRIN) entered into Open Market Sale Agreements on **August 29, 2025**, to issue and sell shares of its common stock with an aggregate offering price of up to **$250,000,000**.  **[1786108_0001213900-25-082060_ea025496101ex10-2_trinity.htm:0]** **[1786108_0001213900-25-082060_ea025496101ex10-4_trinity.htm:0]** **[1786108_0001213900-25-082060_ea025496101ex10-1_trinity.htm:0]** 
- The sales agents for this offering include **B. Riley Securities, Inc.**, **Jefferies LLC**, **Keefe, Bruyette & Woods, Inc.**, and **Compass Point Research & Trading, LLC**.  **[1786108_0001213900-25-082060_ea025496101ex10-2_trinity.htm:0]** **[1786108_0001213900-25-082060_ea025496101ex10-4_trinity.htm:0]** **[1786108_0001213900-25-082060_ea025496101ex10-1_trinity.htm:0]** 
- The company has established a "Floor Price" for these sales, which cannot be less than **$1.00** without prior consent, or less than the company's then-current net asset value per share.  **[1786108_0001213900-25-082060_ea025496101ex10-2_trinity.htm:0]** **[1786108_0001213900-25-082060_ea025496101ex10-4_trinity.htm:0]** **[1786108_0001213900-25-082060_ea025496101ex10-1_trinity.htm:0]** 
- Trinity Capital Inc. has been regulated as a **business development company (BDC)** by the U.S. Securities and Exchange Commission since **January 16, 2020**.  **[1786108_0001213900-25-082060_ea025496101ex10-2_trinity.htm:9]** **[1786108_0001213900-25-082060_ea025496101ex10-3_trinity.htm:9]**

Trinity Capital (TRIN)